GlassScriptPhysician profile
Brandi L Smith
NPI 1093293318
$2,394.92
in general payments reported to CMS, 2019-2025
22 companies · $8.94 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $928 · 2023: $82.60 · 2024: $303 · 2025: $8.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $643.53 | 2021-2022 | |
| Lilly USA, LLC | $363.09 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $284.51 | 2021-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $175.91 | 2021-2022 | |
| Amarin Pharma, INC. | $119.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $107.51 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $79.11 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $77.02 | 2021-2022 | |
| Esperion Therapeutics, INC. | $72.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $64.59 | 2022-2023 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $55.87 | 2021-2023 | |
| Dexcom, INC. | $54.53 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $51.80 | 2021-2022 | |
| Mylan Specialty L.P. | $44.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.46 | 2021-2022 | |
| Lundbeck LLC | $24.12 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.05 | 2022 | |
| Almatica Pharma LLC | $19.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.96 | 2023 | |
| Phathom Pharmaceuticals, INC. | $8.94 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.